4 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 6 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Reduced Intensity Conditioning: new trials by email Literature Review of Reduced Intensity Conditioning trials Research Report on Reduced Intensity Conditioning
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2018-09-04 | 2026-03-17 |
| Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L - Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 354 | 2015-11-19 | 2026-10-26 |
| Haploidentical Hematopoietic Stem Cell Transplantation peripheral blood stem cell graft that are CD34+ selected - Sickle Cell-thalassemia Disease, Thalassemia | Phase 1 | Completed | Catherine Bollard | 7 | 2015-01-01 | 2024-12-19 |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning - Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | New York Medical College | 20 | 2014-03-01 | 2022-10-27 |
| Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning - Non Malignant Disorders, Immunodeficiencies | Phase 1 | Completed | Duke University | 22 | 2008-10-01 | 2014-08-13 |
| Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning reduced intensity conditioning - Myeloma | Phase 2 | Completed | Hospices Civils de Lyon | 13 | 2007-01-01 | 2025-12-19 |
| Dose-reduced Versus Standard Conditioning in MDS/sAML Reduced Intensity Conditioning, Myeloablative conditioning - Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia | Phase 3 | Terminated | European Society for Blood and Marrow Transplantation | 129 | 2004-05-01 | 2015-04-03 |
| Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant Reduced intensity conditioning, Rapid immunosuppressive taper, Prophylactic donor leukocyte infusions - Multiple Myeloma, Lymphocytic Leukemia, Chronic | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 54 | 2003-04-01 | 2017-03-08 |
| Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Reduced intensity conditioning, Prophylactic donor leukocyte infusions - Leukemia, Lymphoma, Low-Grade | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 30 | 2000-03-01 | 2007-04-23 |
Autoimmune Diseases (2) · Common Variable Immunodeficiency (2) · Immune System Diseases (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Opportunistic Infections (2) · T cell immunodeficiency primary (2) · Thalassemia (2) · Anemia, Diamond-Blackfan (1) · Hemoglobinopathies (1) · Hodgkin Disease (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1)
National Cancer Institute (NCI) (2) · University of Michigan Rogel Cancer Center (2) · Catherine Bollard (1) · Duke University (1) · European Society for Blood and Marrow Transplantation (1) · Hospices Civils de Lyon (1) · New York Medical College (1) · OHSU Knight Cancer Institute (1)
United States (8) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Russia (1)
Dimana Dimitrova, M.D. (2) · Afanasyer Boris (1) · Allione Bernardino (1) · Augustin Ferrant, MD (1) · Axel R Zander, MD (1) · Dietger Niederwieser, MD (1) · Domink Heim, Prof. (1) · Gerhard Behre (1) · Ghulam J Mufti, MD (1) · Giorgio Lambertenghi Deliliers (1) · Jennifer N Saultz (1) · John E. Levine, MD, MS (1) · John E. Levine, MS MD (1) · Kai Hubel (1) · Kathrin Haifa Al-Ali, MD (1)
PMID 23994781, PMID 24296492, PMID 36240296
2005 (1)